2BB score and signals
Nektar Therapeutics’s current 2BB score is 46 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 67 | High |
| Momentum | 58 | Stable |
| Financial strength | 5 | Very Weak |
| Quality | 80 | Strong |
| Risk | 60 | High |
Company facts
| Headquarters | San Francisco, California, United States |
| Founded | 1990 |
| Employees | 63 |
| 52-week range | $33.40 – $109.00 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-03-10 | — | -2.7496 | — | $10.74M |
| 2026-11-05 | — | -2.1412 | — | $10.63M |
| 2026-08-13 | — | -2.0243 | — | $10.63M |
| 2026-05-07 | -1.82 | -1.6267 | $10.86M | $10.85M |
Related companies
